Abstract As targeted therapies advance treatment for brain tumors, standard clinical trial endpoints of survival, progression free survival and radiographic response have become insufficient to capture clinical benefit. Brain cancer is a malignancy with neurodegenerative features. In this setting prolongation of life and/or radiographic stability are less clinically meaningful if neurocognitive function substantially declines. Hence evaluation of new therapeutic strategies should routinely include periodic assessment of neurocognitive function.
- Content Type Journal Article
- Category Methods and Clinical Tools for Outcome Assessments
- Pages 1-4
- DOI 10.1007/s11060-012-0813-8
- Authors
- Christina A. Meyers, Department of Neuro-Oncology, M.D. Anderson Cancer Center, Houston, TX, USA
- Edwin P. Rock, Otsuka Pharmaceutical Development and Commercialization Inc, Rockville, MD, USA
- Howard A. Fine, Neuro-Oncology Branch, National Cancer Institute, Bethesda, MD, USA
No comments:
Post a Comment